Theratechnologies Inc T.TH

Theranostics

[Lee430]

Molecular-targeted liquid radiation, is this simular to what jfm1330 has been refering to that Thera could use with the peptide or a completly different new therapy? 

https://www.dailybulletin.com/2021/07/24/new-hope-in-the-fight-against-prostate-cancer-we-can-win-this-war/

[jfm1330]

This is exactly what I am talking about relentlessly here, but for prostate cancer. Personnally, I was talking about neuroendocrine cancers, which was the cancer for which the first PDCs developped with radioisotopes. In this case it's a more recent development in prostate cancer. It uses a tripeptide linked to a non peptidic part. This peptide based molecule has affinity for the PSMA receptor

[jfm1330]

I should add that the prostate cancer version (Lu177-PSMA) is following the same path as the neuroendocrine cancer one (Lu177-Dotatate or Lutathera). It was first available in Europe, and that for many years, before it was finally approved in the US and Canada. So Lu177-PSMA should follow the same path. Novartis is behind it. That being said, the imaging version with Gallium 68 is already approved

[Lee430]

I asked Leah if she would forward the article to Marsolais, I don't have the chops to do any more than that, hopefully JFM1330 has presented a compelling argument to them for at least looking into this. 

[jfm1330]

What need to be understood, is that the trailblazing job in that field has been done in Europe in the last 20 years. The pioneering job has been long and careful, but now this field is well known and tools are easy to adapt to new peptides. Thera would not do this job alone, they need to partner with knowlegable scientists in the field. As I wrote before here, there is knowhow in the province of

[jfm1330]

DOTA-Lu177 and DOTA-Ga68 are also in clinical trials against pancreatic cancer. They are linket to something called ABM-5G. I have not been able to find its nature or structure, so if it is a peptide. It is aiming at a protein on the membrane of pancreatic cancer. It has been developped at UCDavis. It's an American university, so I guess it's good enough... https://studypages.com/s/a

[qwerty22]

It's a perfect example. Looks like this spun out of Case Western bioengineering department, think of Cleveland Clinic if you want references. This guy is the brains behind it. https://engineering.case.edu/profiles/zxl125 He's been publishing for 20 years on the subject. Everything says this is a company with deep roots in the subject. No doubt surrounded by all the necessary

[scarlet1967]

I am starting to think your skepticism lies every where in case of THTX, I believe if they can convince you, they can convince anyone. Maybe they should start having practice sessions with you first before trying to strike deals or promote their programs:)....

[Bucknelly21]

QWERTY sounds like Thtx ran over his dog when talking anything Thtx 

[scarlet1967]

I actually agree with qwerty, they need to have a clear PoC first before allocating resources to other projects, they may ending up chasing multiple cancers too. They need to conclude the NASH program one way or the other, I don't think absent a partner they just give it up but most likely start the futility analysis and if they end up with positive results  then they are in much better

[qwerty22]

I'm being critical of Jfm here not thtx, just so you know. The company aren't doing this work and it doesn't particularly bother me that they aren't. If they start doing this work I'll take an interest. I don't think the company are set up to do this work but that might not matter. In response to a Q about companion diagnostics/screening tools Christian said they were